FDA panel narrowly endorses empagliflozin’s cardiovascular mortality benefitJune 29, 2016DiabetesLipid Disorders
Benefits of lifestyle intervention only brief in some patients with type 2 diabetesJune 23, 2016DiabetesObesity
Pioglitazone safe and effective for steatohepatitis in T2DMJune 20, 2016Lipid DisordersDiabetesObesity
